Purpose Combining CDK4/6 inhibitors and endocrine therapy (ET) improved outcomes for
the treatment of metastatic HR+/HER2− breast cancers. Here, we performed a meta-analysis …

Simple Summary Breast cancer is one of the major causes of cancer-related morbidity and
mortality in women worldwide. Despite recent improvements in adjuvant treatment of …

In the last decade, immunotherapies have revolutionised anticancer treatment. However,
there is still a number of patients that do not respond or acquire resistance to these treatments. …

Approximately 10% of breast cancers are associated with the inheritance of a pathogenic
variant (PV) in one of the breast cancer susceptibility genes. Multiple breast cancer …

Many of the cellular abnormalities present in solid tumors are structural in nature and involve
the proteins of the extracellular matrix (ECM). Periostin is a protein produced and secreted …

The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-induced
premature ovarian failure. Pharmacological temporary ovarian suppression obtained …

Introduction: Antiandrogens are a treatment option in patients with prostate cancer, given
either in combination with androgen deprivation or, in selected cases, as monotherapy. New-…

The study of circulating cancer-derived components (circulome) is considered the new frontier
of liquid biopsy. Despite the recognized role of circulome biomarkers, their comparative …

Healthy carriers of BRCA1/2 pathogenic variants (PVs) may benefit from risk-reducing
measures of proven efficacy. The main approach to identify these individuals is cascade testing, …

Background Adjuvant chemotherapy is the standard of care in high-risk early breast cancer
patients. Dose-dense should be the preferred schedule of administration. However, its long-…